<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR13">
 <label>13.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yoshikawa</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Terashima</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Mizusawa</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Nunobe</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Nishida</surname>
    <given-names>Y</given-names>
   </name>
   <name>
    <surname>Yamada</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Kaji</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Fukushima</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Hato</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Choda</surname>
    <given-names>Y</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial</article-title>
  <source>Lancet Gastroenterol Hepatol</source>
  <year>2019</year>
  <volume>4</volume>
  <issue>3</issue>
  <fpage>208</fpage>
  <lpage>216</lpage>
  <pub-id pub-id-type="doi">10.1016/S2468-1253(18)30383-2</pub-id>
  <pub-id pub-id-type="pmid">30679107</pub-id>
 </element-citation>
</ref>
